Setting The Pace In The Cancer Race - Moffitt

BABY YOU CAN DRIVE MY CAR(T): FUTTHERAPY AND MANUFACTURING11:30 a.m. - 12:30 p.m. - Ferman Family Conference RoomMODERATORAdam Mailloux, PhDAssistant MemberImmunology DepartmentAssistant Director, Cell Therapies FacilityMoffitt Cancer CenterDr. Mailloux is an Assistant Member in the Department of Immunology. Prior to joining the faculty,Dr. Mailloux served as postdoctoral fellow and research scientist at Moffitt where he explored thepathophysiology of hematopoietic disease in the context of immune homeostasis as well as the developmentof novel methods to isolate and expand tumor-reactive infiltrating lymphocytes for therapeutic use. Hiscurrent research interests focus on the design and implementation of novel approaches to boost theeffectiveness of anti-cancer immunotherapies. His research programs complement the strengths of theImmunology Program and ensure the successful evolution of our state-of-the-art Cell Therapy Facility,where he also serves as the Assistant Technical Director. Adam received his bachelor’s degrees in chemistryand biochemistry from the University of Charleston and his PhD in microbiology and immunology from theMedical University of South Carolina.PANELISTSCecile Chartier, PhDVice President, ResearchIovance BiotherapeuticsCécile Chartier, Ph.D. is currently serving as VicePresident of Research at Iovance Biotherapeutics.She led OncoMed Pharmaceuticals’ TargetValidation group from 2005 to 2017, as a SeniorDirector. From 2001 to 2004, Dr. Chartier was aScientist III in Berlex Biosciences’ Gene Therapydepartment. Her career as a scientist started atthe French Biotechnology company Transgene. Dr.Chartier is a Molecular Biologist by training. Sheobtained her Bachelor’s, Master’s, and Ph.D. in 1987,1988, and 1993 from the Université Louis Pasteurof Strasbourg, France. She pursued post-doctoraltraining at Harvard Medical School in Boston from1997 to 2000, followed by one year at StanfordUniversity in 2001.William Go, MD, PhDSr. Vice President &Head of DevelopmentA2 BiotherapeuticsAs Senior Vice President and Head of Developmentat A2 Biotherapeutics, Will’s organizationoversees process development through to clinicaldevelopment, utilizing A2’s novel platformtechnology to develop immunocellular therapy inserious diseases including cancer. Prior to A2 Bio,Will worked at Kite Pharma, where he led the ZUMA1 pivotal study and FDA approvals of YESCARTA .Prior to Kite Pharma, Will worked at Amgen wherehe played an instrumental role in the clinicaldevelopment of Vectibix in colorectal cancer aswell as identifying new predictive biomarkers, as aMedical Director in Global Clinical Development. Willreceived his BA in Biology from Carleton Collegeand then his PhD as well as MD from the Universityof California San Diego. He also completed hisinternal medicine residency, hematology/oncologyfellowship at UCSD.

TURE CHALLENGES WITH CELLTJ LangerFounder & CEOMyst TherapeuticsTJ Langer has a background in biomedical engineeringand has been in the industry for 15 years. As one ofthe early employees at Kite Pharma, he worked todevelop the successful, FDA-approved YESCARTA CAR-T product from pre-IND to BLA approval. Afterthe Gilead acquisition, he led the development ofengineered T cell products targeting neoantigens.His new biotechnology company, Myst Therapeutics,aims to make cancer cell therapy for solid tumorsmore effective and accessible to patients.Paul Stead, PhDVice PresidentBusiness DevelopmentAdaptimmune TherapeuticsPaul Stead is Vice President of Business Developmentat Adaptimmune Therapeutics. Adaptimmune is aleader in the discovery and development of TCR T-celltherapies for treatment of solid tumors. Prior tojoining Adaptimmune, Paul worked in senior businessdevelopment roles at Inovio Pharmaceuticals,Nimbus Therapeutics, and GlaxoSmithKline. Paulobtained a Bachelor of Pharmacy degree from theUniversity of Bath, UK, and holds a PhD (Universityof Nottingham, UK) and an MBA (Lehigh University,Bethlehem, PA).José Vidal, PhDSenior Vice PresidentQuality Assurance &Process SciencesAtara BiotherapeuticsDr. José Eduardo Vidal joined Atara Biotherapeuticsin 2018. Prior to Atara, Dr. Vidal served as VicePresident, Drug Substance Operations at Amgenmanaging a 500 million budget across theirglobal drug substance manufacturing network.He was also Amgen’s Executive Director, ProcessDevelopment, where he collaborated closely withmanufacturing and quality to accelerate the deliveryof a product portfolio comprised of over ten Phase3 products. José also held several senior roles atPfizer, as well as Wyeth and Biovail with a focus onglobal manufacturing and quality operations. Joséreceived his bachelor’s degree in molecular biology,master’s degree in molecular endocrinology andbiochemistry and PhD in biochemistry and cellularmolecular biology all from the University of PuertoRico, Rio Piedras.SESSIONSPONSORED BY

DRIVING YOUR FUNDS TO THE FINISHREVEAL WHAT COUNT 2:00 p.m. - 3:00 p.m. - Ted and Marty Couch AuditoriumMODERATORTodd CreechPartner, HealthQuest CapitalTodd Creech is a partner at HealthQuest Capital, a growth equity, private equity firm investing in commercialstage companies across the healthcare industry. Over the last 10 years, Todd has served as a healthcare CFO,helping build several successful companies to profitable exits. He joined HealthQuest in 2016 to bring hisoperations and financial experiences to innovative companies that are primed for growth with the right planand execution. He currently serves as board member of HealthQuest portfolio companies Alcresta, BioIQ, andEtairos and an observer for HealthChannels, Springbuk, InMediata, Avedro, and Venus Concept. During hisCFO tenure, he has raised more than 500M in equity and debt, helping to build operations and companiesthat generated over 3.5B in exits. Todd holds bachelor’s degrees in Finance and Accounting from Miami(Ohio) University and an MBA from Duke University.PANELISTSJames Bianco, MDFounder and Executive ChairmanTuHURA BioPharma, Inc.Dr. Bianco is the principle founder and ExecutiveChairman of TuHURA BioPharma, an immunooncology start up spun out of the MoffittCancer Research Center. He also serves as ChiefDevelopment Officer at Drais Pharmaceuticalsfocusing on identifying, acquiring or licensing noveldrug candidates for new start-ups. Previously, heserved as the principal founder and CEO of CTIBiopharma for 24 years, leading the company tothe commercial launch of 3 novel therapeutics. Dr.Bianco earned his M.D. from the Mount Sinai IcahnSchool of Medicine and completed his residencyat the Mount Sinai Medical Center in NYC. Hecompleted his fellowship in Hematology/Oncologyat the University of Washington/Fred HutchinsonCancer Research Center (FHCRC) where he wasa member of the faculty and Director of the BoneMarrow Transplant Unit. He is an inventor on 16issued patents.Benjamin Chen, PhDVenture PartnerPanacea VentureDr. Benjamin Chen is a Venture Partner withPanacea Venture, a global life science venturefund. Most recently, Benjamin served as the CEOof ImaginAb, Inc., a company developing a cuttingedge platform to address an urgent unmet need inimmuno-oncology. Immediately before that, he wasthe Chairman and CEO of London based ImmuneTargeting Systems, leading the immune therapycompany through significant strategic growth,innovative product development and establishinga presence in France and North America. Prior toreturning to operational roles, he spent nine yearsas a Managing Director at Burrill & Company, aglobal life sciences venture firm where he evaluatedinvestment opportunities, assisted a global clientelein completing licensing, partnering and M&Atransactions. Dr. Chen received his academic trainingin Microbiology and Immunology at the Universityof Wisconsin-Madison and Stanford University.

LINE: VCs AND ENTREPRENEURSGeoffrey Duyk, MD, PhDFounder and Managing PartnerCircularis PartnersDr. Duyk is Founder and Managing Partner ofCircularis Partners, a group focused on supportingtechnology-enabled companies that advance thecircular economy and promote sustainability aswell as resource efficiency. Prior to Circularis,Dr. Duyk was the Managing Director and Partnerof TPG Alternative & Renewable Technologies/TPG Biotechnology. Dr. Duyk has also heldseveral executive roles in industry research anddevelopment. Prior to industry, Dr. Duyk was anAssistant Professor at Harvard Medical Schoolin the Department of Genetics and an AssistantInvestigator of the Howard Hughes MedicalInstitute. Dr. Duyk holds an MD and PhD from CaseWestern Reserve University. He completed hismedical and fellowship training at the University ofCalifornia, San Francisco. While at UCSF, Dr. Duykwas a fellow of the Lucille P. Markey Foundation andwas awarded a post-doctoral fellowship from HHMI.Michael Luther, PhDPresident and CEOTeewinot Life Sciences Corp.Dr. Luther is currently the CEO of Teewinot LifeSciences, a global leader in the development andproduction of cannabinoids and their derivatives forconsumer and pharmaceutical markets. Previousroles include the Vice President and Head of R&Dfor Merck-Canada leading Merck’s global discoveryefforts in inflammation and metabolic disease, aswell multiple roles with GlaxoSmithKline includingVice President in Discovery Research. At GSK, heled multiple teams that led to the successful launchof new therapeutics in oncology and metabolicdisease. Dr. Luther holds Bachelor of Sciencedegrees from North Carolina State University, a PhDfrom the St. Louis University School of Medicine,and an MBA from Duke University. He is the authorof over 65 publications and holds issued patents indiagnostics and pharmaceuticals.Myla Lai-Goldman, MDFounder and ExecutiveChairpersonGeneCentric TherapeuticsDr. Lai-Goldman is Co-Founder and ExecutiveChairperson of GeneCentric Therapeutics. Sheserved as CEO and president from 2011 through2018. Dr. Lai-Goldman spent more than 18 yearsat Laboratory Corporation of America (LabCorp),the last 10 years as Executive Vice President, ChiefMedical Officer and Chief Scientific Officer. During hertenure at the company, she led all clinical, scientificand medical activities, including the introductionof more than 400 clinical assays. Her experienceincludes the development of partnerships, licensing,and acquisitions. After leaving LabCorp, Dr. LaiGoldman became a Venture Partner at HatterasVenture Partners and is the managing partnerof Personalized Science, a consulting companyfounded to assist customers achieve successfuladoption of innovative diagnostics. Dr. Lai-Goldmanreceived her BS from the University of Pennsylvaniaand MD from Columbia University. Dr. Lai-Goldmanis board-certified in anatomic and clinical pathology.

THE IMMUNOTHERAPY RACE: PUTTING2:00 p.m. - 3:00 p.m. - Ferman Family Conference RoomMODERATORBrian Ruffell, PhDAssistant MemberImmunology DepartmentMoffitt Cancer CenterBrian Ruffell, PhD received his doctorate in Immunology at the University of British Columbia, completedpostdoctoral studies in Cancer Immunology at the University of California, San Francisco and Oregon Healthand Science University, and joined the faculty at the Moffitt Cancer Center and Research Institute in Tampa,Florida in 2015. The Ruffell lab is focused on discovering how macrophages and dendritic cells regulate theefficacy of standard-of-care therapeutics, especially in poorly immunogenic, hormone-driven malignancies,with the ultimate goal of targeting these cells to enhance anti-tumor immunity.PANELISTSMark Cantwell, PhDChief Scientific OfficerMemgenMark Cantwell, PhD is the Chief Scientific Officer ofMemgen, LLC. In this role, he is responsible for thedevelopment of Memgen’s cancer immunotherapypipeline, including its lead drug product MEM-288,a powerful new oncolytic adenovirus developed incollaboration with scientists at Moffitt Cancer Center.Dr. Cantwell has extensive research and industryexperience in cancer immunotherapy drug discoveryand development with a special focus on viralcancer immunotherapy. Dr. Cantwell has authorednumerous peer-reviewed publications, includingarticles in the high-impact scientific journals suchasNature Medicine, Nature Communications,and Journal of Clinical Investigation. Dr. Cantwellis an inventor on multiple technologies includingMEM-288 which directly targets cancer cells andsupercharges the immune system. Dr. Cantwell hasa PhD in Biomedical Sciences from the University ofCalifornia San Diego where he specialized in cancerimmunotherapy and gene therapy advancements.Matthew Collinson-Pautz, PhDSenior ScientistBellicum PharmaceuticalsMatthew Collinson-Pautz is a Senior Scientistin Translational Research at Bellicum. JoiningBellicum in 2016, Matthew initially worked inthe early preclinical discovery group developingnovel technologies to enhance the performanceof adoptive cell therapies, including CAR-T. Fromthere, he transitioned to the clinical side ofdrug development, where he currently works onbiomarkers for Bellicum’s lead GoCAR-T program,BPX-601, in advanced solid tumors. He receivedhis BA from Augustana College and his PhD inTranslational Biology and Molecular Medicine fromBaylor College of Medicine.

G YOUR IMMUNE SYSTEM IN DRIVEPatricia Lawman, PhDCo-Founder and CEOMorphogenesis, Inc.Patricia Lawman, PhD, co-founder and CEOof Morphogenesis, Inc., received her graduateeducation in molecular biology and immunologyfrom the College of Medicine at the University ofFlorida where she served as a Postdoctoral Fellowin Pediatric Hematology and Oncology. Prior tofounding Morphogenesis, Dr. Lawman was DivisionDirector of Cancer Molecular Biology at the WaltDisney Memorial Cancer Institute in Orlando, FL,where she initiated and coordinated molecularbiology, gene targeting and universal stem cellprojects. She has held adjunct faculty positions atthe University of Central Florida and the Universityof South Florida and has served on numerouscommittees at local/state/federal levels. Dr. Lawmanholds over 25 patents and as many publications, andhas received multiple honors including 2012 TampaBay Business Journal Technology Business Womanof the Year. Under her direction, Morphogenesishas raised over 25M and is about to enter Phase IIhuman clinical trials for its cancer immunotherapy.Nathalie Scholler, MD, PhDDirector, Translational MedicineKite PharmaDr. Scholler is a Director in the TranslationalMedicine department of Kite, a Gilead companywhere she manages Kite’s External ResearchCollaborations with academic laboratories toadvance the understanding of cellular therapymechanisms of action and resistance. Previously,Dr. Scholler led the Cancer Immunology group atSRI international, developing novel strategies ofcancer immunoprevention and targeted imagingwith recombinant antibodies (nanobodies). Priorto SRI, Dr. Scholler was an Assistant Professor atthe University of Pennsylvania and her laboratoryisolated various recombinant antibodies. Herreagents have been used both as diagnostic assays(biobodies) and for clinically relevant applications,including to target CAR-T cells in collaboration withCarl June’s laboratory. Dr. Scholler was born andeducated in Marseille, France, where she obtainedan MD and a PhD in Immunology. She has published60 manuscripts, editorials, and book chapters, aswell as 13 granted patents.SESSION SPONSORED BY

COMMUNITY PARTNERSBIOFLORIDAFLORIDA OALITIONGREATER TAMPACHAMBER OFCOMMERCEFLORIDAVENTUREFORUMPINELLAS COUNTY EDCTAMPA BAYINNOVATIONCENTERGOVERNMENT PARTNERCOMING SOON15TH ANNUAL CONFERENCEBUSINESSOFBIOTECHLook for our email announcing the 2021 date and Keynote SpeakerTo sign up for updates, email: innovation@moffitt.org

OFFICE OFINNOVATIONAND INDUSTRYALLIANCESMoffitt Cancer Center, a standalone institution located inTampa, Florida, has a majorresearch enterprise dedicatedto the prevention and cureof cancer. Moffitt’s interdisciplinary research teamsand entrepreneurship culturecreates a fertile ground forinnovation.For licensing and researchcollaboration opportunitiescall 813-745-6828 or emailinnovation@moffitt.org

THANKS TO OUR SPONSORS PROFESSIONAL SYSTEMSPrinting & Promotional Products

Moderator: Dr. Ross Mitchell, Moffi Cancer Center Moderator: Dr. Adam Mailloux, Moffi Cancer Center Moderator: Todd Creech, HealthQuest Capital Moderator: Dr. Brian Ruffell, Moffi Cancer Center Charles Gibson, interna onally renowned journalist and former Good Morning America o AGENDA